Evidence map›Paper›PMID 41401163›Full record

ArticlePloS one2025

Optimizing the preparation of labeled N-glycans for rapid, simplified, and high-precision analysis.

Riko Makino, Shunji Natsuka

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Riko MakinoDepartment of Life and Food Sciences, Graduate School of Science and Technology, Niigata University Ikarashi-nino-cho, Nishi-ku, Niigata, Japan.
Shunji NatsukaDepartment of Life and Food Sciences, Graduate School of Science and Technology, Niigata University Ikarashi-nino-cho, Nishi-ku, Niigata, Japan.ORCID https://orcid.org/0000-0003-1726-8946

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycan structures hold promise as biomarkers for the early detection of diseases, owing to their sensitive reflection of cellular states. However, glycan analysis remains complex and time-consuming, and the use of hazardous chemicals in traditional hydrazinolysis methods presents a significant barrier to broader application and cross-disciplinary research. To enable efficient glycan biomarker discovery, we aimed to develop a simple and accurate N-glycan analysis method capable of high-throughput sample processing. A key feature of this study is the use of pyridylamination, a fluorescent labeling technique that enables high isomer separation efficiency in reversed-phase LC/MS. After comparing various methods for N-glycan release and purification, we identified Rapid PNGase F (New England Biolabs) and BlotGlyco (Sumitomo Bakelite) as optimal for this application. To improve accuracy by reducing artifact formation, the BlotGlyco protocol was modified from the manufacturer's original instructions. Using this optimized workflow, we successfully analyzed human serum, human urine, and CHO-K1 membrane fractions, demonstrating that distinct glycan structures in each sample type could be effectively separated and quantified. This work supports the broader adoption of glycan analysis across diverse research fields.

Indexed as

PolysaccharidesAnimalsCHO CellsChromatography, Reverse-PhaseCricetulusHumansPeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidasePeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidasePolysaccharides

Identifiers

PMID41401163
PMCPMC12707664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.